Last reviewed · How we verify
Acalabrutinib Treatment D
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.
At a glance
| Generic name | Acalabrutinib Treatment D |
|---|---|
| Also known as | AT |
| Sponsor | AstraZeneca |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a key role in the signaling pathways of B cells.
Approved indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
Common side effects
- Headache
- Diarrhea
- Nausea
- Fatigue
- Muscle pain
Key clinical trials
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Avo In R/R And Previously Untreated MCL (PHASE1, PHASE2)
- Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (PHASE2)
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (PHASE1, PHASE2)
- APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (PHASE1, PHASE2)
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (PHASE2)
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (PHASE2)
- A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib Treatment D CI brief — competitive landscape report
- Acalabrutinib Treatment D updates RSS · CI watch RSS
- AstraZeneca portfolio CI